Navigation Links
Biostar Pharmaceuticals, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing

XIANYANG, China, March 3 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"), the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), and a variety of pharmaceutical products and medical nutrients today announced it will present at the Rodman & Renshaw Annual China Investment Conference held March 7-9 in Beijing, China. Presentation details are noted below.

    Date:        March 8, 2010
    Time:        12:20 pm Beijing Time
    Location:    Ballroom II, The Regent Hotel, Beijing China
    Presenter:   Mr. Rongua Wang - Chairman and CEO
                 Mr. Michael Lan - VP of Finance

Conference participation is by invitation and registration is mandatory. For more information on the conference, contact your Rodman & Renshaw representative or visit .

About Rodman & Renshaw (Nasdaq GM: RODM)

Rodman & Renshaw Capital Group, Inc., (NasdaqGM: RODM) through its subsidiaries, engages in investment banking business. It offers corporate finance services focusing on various public and private equity products, which include private investment in public equity, registered direct offerings, private placements, and public offerings, as well as provides Collateralized Acquisition Pool, a product used to facilitate a targeted acquisition. The company also involves in strategic advisory services, which include identifying and/or evaluating acquisition targets or acquirers; providing valuation analyses; evaluating and proposing financial and strategic alternatives; rendering fairness opinions; advising on timing, structure, and pricing of transaction; assisting in negotiating and closing a transaction; advising on the sale process; and assisting in preparing a memorandum or other sales materials. In addition, it provides merchant banking and asset management services. Rodman & Renshaw Capital Group serves public and private biotechnology companies. The company is headquartered in New York, New York.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary in China, develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products, two prescription-based pharmaceuticals and thirteen nutrients. The Company has adopted international standards, holds one patent and is in the process of applying for two patents.

Safe Harbor

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our S-1 dated June 27, 2008, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, our 10-K for the year ended December 31, 2008, and other recent filings. These filings are available at . We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

    For further information, contact:

     Ms. Elaine Zhao, CFO
     Tel:   +1-626-456-2789

     John Mattio
     HC International, Inc.
     Tel:   +1-203-616-5144 (US)

SOURCE Biostar Pharmaceuticals, Inc.

Back to top



SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Biostar Pharmaceuticals, Inc. Announces Change of Auditor
2. Biostar Pharmaceuticals, Inc. to Present at the Maxim Group Growth Conference on September 29 at 2:00pm ET
3. Biostar Pharmaceuticals, Inc. Receives Government Approvals for Three New Products
4. Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan
5. Biostar Pharmaceuticals, Inc. Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base
6. Biostar Pharmaceuticals, Inc. Completes 8.6-Acre Land Purchase to House New Raw Materials Processing Plant
7. DUSA Pharmaceuticals, Inc.(R) to Host Fourth Quarter and Full Year 2009 Financial Results and Corporate Highlights Conference Call
8. Thomas Pharmaceuticals, Ltd to Merge with Global Medical Equipment of AZ
9. PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings
10. With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals, Inc. and Launch Effort to Educate Americans
11. Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... lower prices in an early celebration of the early holiday shopping season. Starting ... $29.95 each (normally $33.95 ea). Black Friday promotional pricing is in addition to ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... ... now certified to offer their patients the many benefits of the revolutionary BIOLASE ... the sharp cutting and scraping tools traditionally used by a dentist in ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to seek treatment ... dental implants at her Mississauga, ON practice. Dr. Williams has been providing dental ... dental implants. , Missing teeth can lead to a variety of complications if ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Charitable giving is ... donations are made in the last five weeks of the year totalling over $358 ... in 2012 to connect the nation’s charities with those individuals who want to “give ...
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... - Will Also Offer Point ... (CME) --> - Will Also Offer ... (CME) --> - Will ... Education (CME) Elsevier , a world-leading ... feature latest diagnostic imaging textbooks and decision support tools, as well ...
(Date:11/25/2015)... --> --> ... für das Patent über eine neue Hepatitis-B-Behandlung, welches sie ... an Enyo Pharma vergeben haben. Im Rahmen ... und von Edelris gemeinsam mit seinen Partnern Inserm und ... HBV identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die ...
(Date:11/24/2015)... NEW DELHI , November 25, 2015 ... fear invoked due to repeated failure of IVF cycles. ... Rani Bhatia was totally dejected and had lost all hopes that ... the first Indian miracle child conceived after failure of ... to abroad (UK) before they decided to take one last ...
Breaking Medicine Technology: